Clozapine and the risk of haematological malignancies - Authors' reply
- PMID: 35717958
- DOI: 10.1016/S2215-0366(22)00204-8
Clozapine and the risk of haematological malignancies - Authors' reply
Conflict of interest statement
JT, HT, and AT have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. JT has been a consultant to, an advisor to, or has received honoraria from: Eli Lilly, Evidera, Janssen-Cilag, Lundbeck, Orion, Otsuka, Mediuutiset, Sidera, and Sunovion. JSB is supported by a National Health and Medical Research Council (NHMRC) Boosting Dementia Research Leadership Fellowship and has received grant funding or consulting funds from the NHMRC, Victorian Government Department of Health and Human Services, Dementia Australia Research Foundation, Yulgilbar Foundation, Aged Care Quality and Safety Commission, Dementia Centre for Research Collaboration, Pharmaceutical Society of Australia, GlaxoSmithKline Supported Studies Programme, Amgen, and several aged care provider organisations unrelated to this work. All grants and consulting funds were paid to the employing institution. HT reports personal fees from Janssen-Cilag and Otsuka. All other authors declare no competing interests.
Comment on
-
Clozapine and the risk of haematological malignancies.Lancet Psychiatry. 2022 Jul;9(7):537-538. doi: 10.1016/S2215-0366(22)00154-7. Lancet Psychiatry. 2022. PMID: 35717956 No abstract available.
-
Clozapine and the risk of haematological malignancies.Lancet Psychiatry. 2022 Jul;9(7):538-539. doi: 10.1016/S2215-0366(22)00149-3. Lancet Psychiatry. 2022. PMID: 35717957 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources